Descriptive only
Four point MACE including unstable angina
Type 2 diabetes (adults)
longest follow-upCause specific hazardsEach dose separatelyHazard ratio
1
Randomized trials
2
Treatments
0
Participants
2
Trial arms
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Age (years) prognostic factor; 1 of 1 | Established cardiovascular disease (percent of participants) prognostic factor; 0 of 1 | Kidney function (eGFR) (mL/min/1.73 m2) prognostic factor, effect modifier; 0 of 1 |
|---|---|---|---|
| NCT02465515 S001074 | 64.15 | not reported | not reported |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagBaseline, Established cardiovascular disease: not reported by 1 of 1 trials
- FlagBaseline, Kidney function (eGFR): not reported by 1 of 1 trials
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02465515 | 140.89 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2015 | type 2 diabetes with established cardiovascular disease |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT02465515 | A1 | PLACEBO | 140.89 | contrast, hr | registry:outcomes | ||||
| NCT02465515 | A2 | ALBI_SC_FLEX_30-50_QW | 140.89 | contrast, hr | -0.248 | 0.068 | registry:outcomes |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.